• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前化疗期间肿瘤体积增大是肢体骨肉瘤局部复发的新预测因子。

Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma.

机构信息

Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea.

出版信息

Ann Surg Oncol. 2011 Jun;18(6):1710-6. doi: 10.1245/s10434-010-1536-8. Epub 2011 Jan 11.

DOI:10.1245/s10434-010-1536-8
PMID:21222166
Abstract

BACKGROUND

Known risk factors (surgical margin, tumor necrosis) of local recurrence (LR) in osteosarcoma are determined by results available after surgery. However, relations between preoperative characteristics and LR have not been clearly defined.

METHODS

We compared the clinicopathologic characteristics of 36 osteosarcoma patients with LR and 394 patients without LR after surgery. In addition, prognostic variables were evaluated to establish factors could influence LR.

RESULTS

Compared to the non-LR group, the LR group showed an increase in tumor volume ratio (TVR) during preoperative chemotherapy (P < 0.01), inadequate surgical margin (P < 0.01), and poor histologic response (P < 0.01). Univariate analysis of data from 430 patients revealed that an increased TVR (P < 0.01), inadequate surgical margin (P < 0.01), poor histologic response (P < 0.01), and nonosteoblastic pathologic subtype (P = 0.04) were negatively related to LR-free survival. In multivariate analysis, an elevated TVR (P < 0.01, relative risk = 10.26) and inadequate surgical margin (P < 0.01, relative risk = 5.91) emerged as the key prognostic factors for LR.

CONCLUSIONS

A TVR increase during preoperative chemotherapy could be used to predict patients at high risk of LR. This finding might be useful when considering surgical options to decrease the risk of LR.

摘要

背景

骨肉瘤局部复发(LR)的已知危险因素(手术切缘、肿瘤坏死)是由手术后的结果确定的。然而,术前特征与 LR 之间的关系尚未明确界定。

方法

我们比较了 36 例 LR 患者和 394 例术后无 LR 患者的临床病理特征。此外,评估了预后变量,以确定可能影响 LR 的因素。

结果

与非 LR 组相比,LR 组在术前化疗期间肿瘤体积比(TVR)增加(P < 0.01),手术切缘不足(P < 0.01),组织学反应不良(P < 0.01)。对 430 例患者的数据进行单因素分析显示,TVR 增加(P < 0.01)、手术切缘不足(P < 0.01)、组织学反应不良(P < 0.01)和非成骨病理亚型(P = 0.04)与无 LR 生存呈负相关。多因素分析显示,升高的 TVR(P < 0.01,相对风险= 10.26)和手术切缘不足(P < 0.01,相对风险= 5.91)是 LR 的关键预后因素。

结论

术前化疗期间 TVR 的增加可用于预测 LR 风险较高的患者。当考虑降低 LR 风险的手术选择时,这一发现可能很有用。

相似文献

1
Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma.术前化疗期间肿瘤体积增大是肢体骨肉瘤局部复发的新预测因子。
Ann Surg Oncol. 2011 Jun;18(6):1710-6. doi: 10.1245/s10434-010-1536-8. Epub 2011 Jan 11.
2
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.比较四肢非转移性骨肉瘤新辅助化疗中二联和三联方案的长期疗效。
Oncology. 2011;80(1-2):107-17. doi: 10.1159/000327216. Epub 2011 Jun 14.
3
Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.肢体非转移性骨肉瘤的新辅助化疗及延迟手术。164例患者术前接受大剂量甲氨蝶呤治疗,随后使用顺铂和阿霉素。
Cancer. 1993 Dec 1;72(11):3227-38. doi: 10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c.
4
Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.肢体骨肉瘤的新辅助化疗:原发肿瘤对甲氨蝶呤、顺铂、阿霉素和异环磷酰胺术前治疗的良好反应。初步结果。
Chir Organi Mov. 1995 Jan-Mar;80(1):1-10.
5
Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.局部复发对接受新辅助化疗的肢体骨肉瘤患者生存的影响:一家机构对44例患者的经验。
Cancer. 2006 Jun 15;106(12):2701-6. doi: 10.1002/cncr.21937.
6
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.高剂量异环磷酰胺、高剂量甲氨蝶呤、顺铂和多柔比星用于肢体局限性骨肉瘤患者的新辅助化疗:意大利和斯堪的纳维亚肉瘤研究组的联合研究
J Clin Oncol. 2005 Dec 1;23(34):8845-52. doi: 10.1200/JCO.2004.00.5785. Epub 2005 Oct 24.
7
Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?骨肉瘤患者仅通过化疗和取消手术就能治愈吗?
Cancer. 2002 Nov 15;95(10):2202-10. doi: 10.1002/cncr.10944.
8
Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.青少年和青年骨肉瘤:新进展与争议。梅奥诊所研究。
Cancer Treat Res. 1993;62:333-8.
9
Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: is a good response to preoperative treatment an indication to reduce postoperative chemotherapy?肢体高级别骨肉瘤的新辅助化疗:对术前治疗的良好反应是否意味着可减少术后化疗?
Chemioterapia. 1986 Apr;5(2):140-3.
10
Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results.肢体骨肉瘤的新辅助化疗。术前采用大剂量甲氨蝶呤,随后顺铂和阿霉素进行化疗后,原发肿瘤反应良好。初步结果。
Chemioterapia. 1988 Apr;7(2):138-42.

引用本文的文献

1
Does joint-sparing tumor resection jeopardize oncologic and functional outcomes in non-metastatic high-grade osteosarcoma around the knee?膝关节周围非转移性高级别骨肉瘤保关节肿瘤切除术是否危及肿瘤学和功能结局?
World J Surg Oncol. 2023 Jun 21;21(1):185. doi: 10.1186/s12957-023-03045-2.
2
Development and Validation of Nomogram-Based Prognosis Tools for Patients with Extremity Osteosarcoma: A SEER Population Study.基于列线图的肢体骨肉瘤患者预后工具的开发与验证:一项监测、流行病学和最终结果(SEER)人群研究
J Oncol. 2022 May 12;2022:9053663. doi: 10.1155/2022/9053663. eCollection 2022.
3
Meta-analysis of the prognosis after surgical treatment of osteosarcoma complicated by pathologic fracture.
骨肉瘤合并病理性骨折手术治疗后预后的Meta分析
Am J Transl Res. 2022 Apr 15;14(4):2580-2592. eCollection 2022.
4
Future Directions in the Treatment of Osteosarcoma.骨肉瘤治疗的未来方向。
Cells. 2021 Jan 15;10(1):172. doi: 10.3390/cells10010172.
5
Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study.保肢手术治疗膝关节周围骨肉瘤的相关预后因素:一项长期随访研究的启示。
Biomed Res Int. 2019 May 2;2019:3215824. doi: 10.1155/2019/3215824. eCollection 2019.
6
Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.18F-FDG摄取增加对检测接受手术切除和人工关节置换治疗的肢体骨肉瘤患者局部复发的价值。
Skeletal Radiol. 2015 Apr;44(4):529-37. doi: 10.1007/s00256-014-2063-7. Epub 2014 Nov 29.
7
High tumor volume and local recurrence following surgery in osteosarcoma: A retrospective study.骨肉瘤术后高肿瘤体积与局部复发:一项回顾性研究。
Indian J Orthop. 2014 May;48(3):285-8. doi: 10.4103/0019-5413.132520.
8
Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.MRI 上的肿瘤近端位置和液-液平面与 IIB 期骨肉瘤的化疗耐药性相关。
Clin Orthop Relat Res. 2014 Jun;472(6):1911-20. doi: 10.1007/s11999-014-3521-1. Epub 2014 Feb 27.
9
Role of surgical margin on local recurrence in high risk extremity osteosarcoma: a case-controlled study.高风险肢体骨肉瘤中手术切缘对局部复发的作用:一项病例对照研究。
Clin Orthop Surg. 2013 Sep;5(3):216-24. doi: 10.4055/cios.2013.5.3.216. Epub 2013 Aug 20.
10
The preparation and characterization of gold-conjugated polyphenol nanoparticles as a novel delivery system.金结合多酚纳米粒子的制备及表征作为一种新型的给药系统。
Int J Nanomedicine. 2012;7:1623-33. doi: 10.2147/IJN.S30060. Epub 2012 Mar 28.